Association of Anti-diabetic Drugs and Covid-19 Outcomes in Patients with Diabetes Mellitus Type 2 and Chronic Kidney Disease: Nationwide Registry Analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Mar 27

PMID 38536830

Authors

Jelena Dimnjakovic

Tamara Buble

Pero Ivanko

Tamara Poljicanin

Sandra Karanovic Stambuk

Hana Brborovic

Ognjen Brborovic

Affiliations

Soon will be listed here.

Abstract

Introduction: Patients with diabetes mellitus type 2 and chronic kidney disease (T2DM-CKD) have a 5 times higher risk of developing severe SARS-CoV-2 infection than those without these 2 diseases. The goal of this study is to provide information on T2DM-CKD and COVID-19 outcomes, with an emphasis on the association with anti-diabetic medications.

Methodology: Study is designed as a retrospective cohort analysis covering the years 2020 and 2021. Data from the National Diabetes Registry (CroDiab) were linked to hospital data, primary healthcare data, Causes of Death Registry data, the SARS-CoV-2 vaccination database, and the SARS-CoV-2 test results database. Study outcomes were cumulative incidence of SARS-CoV-2 positivity, COVID-19 hospitalizations, and COVID-19 deaths. For outcome predictors, logistic regression models were developed.

Results: Of 231 796 patients with diabetes mellitus type 2 in the database, 7 539 were T2DM-CKD (3.25%). The 2-year cumulative incidences of all three studies' outcomes were higher in T2DM-CKD than in diabetes patients without CKD (positivity 18.1% vs. 14.4%; hospitalization 9.7% vs. 4.2%; death 3.3% vs. 1.1%, all p<0.001). For COVID-19 hospitalization, protective factors were SGLT-2 inhibitors use (OR 0.430; 95%CI 0.257-0.719) and metformin use (OR 0.769; 95% CI 0.643-0.920), risk factors were insulin use (1.411; 95%CI 1.167-1.706) and sulfonylureas use (OR 1.226; 95% CI 1.027-1.464). For SARS-CoV-2 positivity protective factors were SGLT-2 inhibitors (0.607; 95% CI 0.448-0.823), repaglinide use (OR 0.765; 95% CI 0.593-0.986) and metformin use (OR 0.857; 95% CI 0.770-0.994). DPP-4 inhibitors showed a non-significant decrease in risk for COVID-19 death (OR 0.761; 95% CI 0.568-1.019).

Conclusion: T2DM-CKD are heavily burdened by COVID-19 disease. Our results suggest no association between antidiabetic drugs and COVID-19 death outcome while SGLT-2 and metformin show to be protective against COVID-19 hospitalization and infection, repaglinide against infection, and insulin and sulfonylureas show to be risk factors for COVID-19 hospitalization and infection. Further research in T2DM-CKD is needed.

Citing Articles

Antidiabetic Medicines Utilisation During Pre-Pandemic, Pandemic and Post-Pandemic Period of COVID-19-Data for Bulgarian Population.

Mitkova Z, Stanimirova D, Manova M, Gerasimov N, Mitov K, Petrova G Healthcare (Basel). 2025; 13(3).

PMID: 39942512 PMC: 11817434. DOI: 10.3390/healthcare13030322.

References

Poljicanin T, Bralic Lang V, Mach Z, Svajda M . Croatian diabetes registry (CroDiab) and implementation of standardised diabetes checklists using Joint Action CHRODIS Recommendations and Criteria. Ann Ist Super Sanita. 2021; 57(1):74-79. DOI: 10.4415/ANN_21_01_12. View

Poljicanin T, Pavlic-Renar I, Metelko Z . [CroDiab NET--electronic diabetes registry]. Acta Med Croatica. 2005; 59(3):185-9. View

Kan C, Zhang Y, Han F, Xu Q, Ye T, Hou N . Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021; 12:708494. PMC: 8481667. DOI: 10.3389/fendo.2021.708494. View

Koncar M, Gvozdanovic D . Primary healthcare information system--the cornerstone for the next generation healthcare sector in Republic of Croatia. Int J Med Inform. 2005; 75(3-4):306-14. DOI: 10.1016/j.ijmedinf.2005.08.007. View

Nassar M, Abosheaishaa H, Singh A, Misra A, Bloomgarden Z . Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis. J Diabetes. 2023; 15(2):86-96. PMC: 9934962. DOI: 10.1111/1753-0407.13359. View

Khunti K, Aroda V, Bhatt D, Bozkurt B, Buse J, Heerspink H . Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes Obes Metab. 2022; 24(11):2071-2080. DOI: 10.1111/dom.14805. View

Belancic A, Kresovic A, Troskot Dijan M . Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?. Clin Obes. 2021; 11(2):e12439. PMC: 7995087. DOI: 10.1111/cob.12439. View

Capak K, Kopal R, Benjak T, Cerovecki I, Drausnik Z, Bucic L . Surveillance system for coronavirus disease 2019 epidemiological parameters in Croatia. Croat Med J. 2021; 61(6):481-482. PMC: 7821359. View

Chudasama Y, Zaccardi F, Gillies C, Razieh C, Yates T, Kloecker D . Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K. BMC Infect Dis. 2021; 21(1):908. PMC: 8418288. DOI: 10.1186/s12879-021-06600-y. View

10.

Qu H, Zheng Y, Wang Y, Li H, Liu X, Xiong X . The potential effects of clinical antidiabetic agents on SARS-CoV-2. J Diabetes. 2020; 13(3):243-252. PMC: 7753367. DOI: 10.1111/1753-0407.13135. View

11.

Bornstein S, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld A . Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020; 8(6):546-550. PMC: 7180013. DOI: 10.1016/S2213-8587(20)30152-2. View

12.

Martin Sanchez F, Martinez-Selles M, Molero Garcia J, Moreno Guillen S, Rodriguez-Artalejo F, Ruiz-Galiana J . Insights for COVID-19 in 2023. Rev Esp Quimioter. 2022; 36(2):114-124. PMC: 10066911. DOI: 10.37201/req/122.2022. View

13.

Hariyanto T, Intan D, Hananto J, Putri C, Kurniawan A . Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2021; 179:109031. PMC: 8397482. DOI: 10.1016/j.diabres.2021.109031. View

14.

Vergara P, Rossi L, Biagi A, Falasconi G, Pannone L, Zanni A . Role of comorbidities on the mortality in patients with SARS-CoV-2 infection: an Italian cohort study. Minerva Med. 2021; 114(2):185-190. DOI: 10.23736/S0026-4806.21.07187-1. View

15.

Gerdes C, Muller N, Wolf G, Busch M . Nephroprotective Properties of Antidiabetic Drugs. J Clin Med. 2023; 12(10). PMC: 10219007. DOI: 10.3390/jcm12103377. View

16.

Pang J, Liu M, Ling W, Jin T . Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment. Obes Med. 2021; 22:100312. PMC: 7785422. DOI: 10.1016/j.obmed.2020.100312. View

17.

Clark A, Jit M, Warren-Gash C, Guthrie B, Wang H, Mercer S . Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020; 8(8):e1003-e1017. PMC: 7295519. DOI: 10.1016/S2214-109X(20)30264-3. View

18.

Cerovecki I, Svajda M . COVID-19 Pandemic Influence on Diabetes Management in Croatia. Front Clin Diabetes Healthc. 2023; 2:704807. PMC: 10012086. DOI: 10.3389/fcdhc.2021.704807. View

19.

Banerjee Y, Pantea Stoian A, Silva-Nunes J, Sonmez A, Rizvi A, Janez A . The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021; 20(11):1309-1315. PMC: 8425441. DOI: 10.1080/14740338.2021.1970744. View

20.

Cunningham S, Carinci F, Brillante M, Leese G, McAlpine R, Azzopardi J . Core Standards of the EUBIROD Project. Defining a European Diabetes Data Dictionary for Clinical Audit and Healthcare Delivery. Methods Inf Med. 2015; 55(2):166-76. DOI: 10.3414/ME15-01-0016. View